The “difficult decision” was made “in order to protect other vital NHS services”, the National Institute for Health and Care ...

Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), ...

After this, the situation will be reviewed by Nice, who will provide further guidance on the rollout. Mounjaro is a ...

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Other work primarily only included glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among individuals with substance use disorders. We also compared GLP-1 RAs to metformin and ...

As anti-obesity medications gain popularity, a new concern has also gained traction among researchers: increased food waste. A self-administered online survey sponsored by Ohio State found that 25% of ...

Eli Lilly's Zepbound outperformed Wegovy in weight loss and key outcomes during the SURMOUNT-5 trial, showing a comparable ...

While surgery has a low risk for complications, when they do occur, they are serious. This may explain why only 5%-10% of ...

Amylyx (AMLX) announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class ...

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2, subcutaneous semaglutide reduced the ...